Connect with us


Metsera, a weight-loss drug developer, secures $290 million in funding



Weight-loss drug developer Metsera raises $290 million in funding, ET HealthWorld

In a recent development, weight-loss drug developer Metsera has successfully raised $290 million in funding, with ARCH Venture Partners leading the investment round, alongside participation from SoftBank and Mubadala Capital. The funding comes at a time when various pharmaceutical companies are vying for a share of the weight-loss drug market, projected to hit $100 billion in value by the end of the decade. Novo Nordisk and Eli Lilly currently lead the market with their popular GLP-1 drugs Wegovy and Zepbound.

Metsera, established in 2022 by ARCH Venture and Population Health Partners, focuses on developing injectable and oral drugs to combat obesity, primarily targeting the GLP-1 mechanism and other biological pathways. The company’s portfolio includes an injectable drug in the early stages of clinical trials, with CEO Clive Meanwell expressing optimism about achieving significant milestones in the next 12 months. The recent $290 million funding round represents the total capital raised by Metsera to date from key healthcare investors through a combination of seed funding and Series A financing.

The funding consortium includes prominent names such as F-Prime Capital, GV, Mubadala Capital, Newpath Partners, SoftBank Vision Fund 2, and other undisclosed investors. Meanwell, the former CEO of The Medicines Company and co-founder of Population Health, refrained from disclosing the valuation at which the funding was secured. His extensive experience in the pharmaceutical industry, including the successful acquisition of The Medicines Company by Novartis in 2019, positions Metsera for potential growth and innovation in the weight-loss drug market.

Click to comment

You must be logged in to post a comment Login

Leave a Reply